Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Cara Therapeutics (Nasdaq: CARA), a biopharmaceutical company, announced that Derek Chalmers, Ph.D., President and CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 11:00 a.m. ET. A live webcast of the event will be available in the Company's News & Investors section on their website. Cara Therapeutics specializes in developing treatments for pruritus by targeting peripheral kappa opioid receptors, with their product KORSUVA™ showing promise in treating chronic kidney disease-associated pruritus.
- None.
- None.
Insights
Analyzing...
STAMFORD, Conn., May 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 11:00 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
jane.urheim@SternIR.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
FAQ
What is the date of the Jefferies Virtual Healthcare Conference for Cara Therapeutics?
Who will represent Cara Therapeutics at the Jefferies Virtual Healthcare Conference?
What is KORSUVA and its significance for Cara Therapeutics?
Where can I access the webcast of Cara Therapeutics' presentation at the conference?
What is the stock symbol for Cara Therapeutics?
